Streetbeat News

Products Services

NAMS

NewAmsterdam Pharma announced that its Phase 2b dose-finding trial evaluating obicetrapib in Japanese patients achieved its primary endpoint with a statistically significant 45.8% median reduction in LDL-C. The trial also showed favorable safety and tolerability, and the data will enable PMDA regulatory path alignment with the rest of the world.

Portfolio Pulse from Benzinga Newsdesk

June 05, 2023 | 11:10 am

ALVR

AlloVir announced results from its Phase 2 randomized, placebo-controlled trial evaluating Posoleucel treatment, showing clinically meaningful reductions in BK viral load compared to placebo.

Portfolio Pulse from Benzinga Newsdesk

June 05, 2023 | 11:09 am

VEEV

Veeva Systems announced that over 450 companies have adopted its Veeva Vault eTMF solution to improve clinical trial efficiency and inspection readiness. The adoption of this technology is expected to streamline trial processes and enhance data quality.

Portfolio Pulse from Benzinga Newsdesk

June 05, 2023 | 11:08 am

GKOS

Glaukos has completed enrollment and randomization in its second Phase 3 trial for Epioxa. The results of this trial, along with the first Phase 3 trial, are expected to support Glaukos' targeted NDA submission for Epioxa by the end of 2024.

Portfolio Pulse from Benzinga Newsdesk

June 05, 2023 | 11:08 am

EYPT

EyePoint Pharmaceuticals has completed enrollment in its Phase 2 PAVIA clinical trial of EYP-1901 for non-proliferative diabetic retinopathy. This marks a significant milestone for the company's drug development program.

Portfolio Pulse from Benzinga Newsdesk

June 05, 2023 | 11:07 am

ONCY

Oncolytics Biotech reported updated Phase 2 data from its BRACELET-1 metastatic breast cancer trial, showing a 71% reduction in disease progression risk and a 37.5% overall response rate with the pelareorep-paclitaxel combination compared to 13.3% with paclitaxel monotherapy.

Portfolio Pulse from Benzinga Newsdesk

June 05, 2023 | 11:07 am

CGEN

Compugen announced that data on COM701, a triple immunotherapy combination for recurrent metastatic MSS endometrial cancer, will be presented at the Society for Immunotherapy of Cancer (SITC) conference. The data shows preliminary durable anti-tumor activity.

Portfolio Pulse from Benzinga Newsdesk

June 05, 2023 | 11:06 am

AVDL

Avadel Pharmaceuticals has launched Lumryz, an extended-release formulation of sodium oxybate, in the US market. Lumryz is designed to treat cataplexy or excessive daytime sleepiness in adults with narcolepsy.

Portfolio Pulse from Benzinga Newsdesk

June 05, 2023 | 11:03 am

BLPH

Bellerophon's Phase 3 REBUILD clinical trial for INOpulse® did not meet its primary endpoint, with iNO45 performing worse than placebo. Secondary endpoints showed minimal difference, and no safety concerns were observed.

Portfolio Pulse from Benzinga Newsdesk

June 05, 2023 | 11:01 am

SYBX

Synlogic has reduced its workforce by 21% and is directing resources towards its late-stage portfolio of product candidates for rare metabolic diseases. This includes prioritizing activities for SYNB1934, SYNB1353, and the ongoing collaboration with Roche.

Portfolio Pulse from Benzinga Newsdesk

June 05, 2023 | 10:51 am